AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31175908 — intervention group
Group type: EXPERIMENTAL
Intervention: Online care
Number of subjects: 296
Study 31175908 — intervention group
Group type: COMPARATOR
Intervention: In-person care
Number of subjects: 296
Study 30358937 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimal maxillary ostial dilation via balloon sinuplasty
Number of subjects: 12
Study 30358937 — intervention group
Group type: COMPARATOR
Intervention: Mega‐antrostomy
Number of subjects: 12
Study 30358937 — intervention group
Group type: COMPARATOR
Intervention: Mini‐antrostomy
Number of subjects: 12
Study 27227651 — intervention group
Group type: EXPERIMENTAL
Intervention: ConfID (Internet intervention)
Number of subjects: 179
Study 27227651 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (control)
Number of subjects: 179
Study 26223493 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine infusion
Number of subjects: 0
Study 26223493 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 0
Study 26223493 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 26223493 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine
Number of subjects: 0
Study 26223493 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 0
Study 23247552 — intervention group
Group type: EXPERIMENTAL
Intervention: Sharp scalpel debridement of painful forefoot plantar callosities in conjunction with a combined therapeutic approach
Number of subjects: 65
Study 23247552 — intervention group
Group type: COMPARATOR
Intervention: Combined therapeutic approach alone
Number of subjects: 65
Study 21251031 — intervention group
Group type: EXPERIMENTAL
Intervention: Rimonabant 20 mg
Number of subjects: 12
Study 21251031 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 18834319 — intervention group
Group type: EXPERIMENTAL
Intervention: 48 weeks of pegylated interferon-alpha-2a (180 microg per week) plus ribavirin (1000-1200 mg/day) therapy
Number of subjects: 308
Study 18834319 — intervention group
Group type: COMPARATOR
Intervention: 24 weeks of pegylated interferon-alpha-2a (180 microg per week) plus ribavirin (1000-1200 mg/day) therapy
Number of subjects: 308
Study 18834319 — intervention group
Group type: EXPERIMENTAL
Intervention: 48 weeks of therapy
Number of subjects: 308
Study 18834319 — intervention group
Group type: COMPARATOR
Intervention: 24 weeks of therapy
Number of subjects: 308
Study 16488138 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine/epinephrine/fentanyl mixture
Number of subjects: 68
Study 16488138 — intervention group
Group type: COMPARATOR
Intervention: Plain 0.5% bupivacaine
Number of subjects: 68
Study 16488138 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 68
Study 13680547 — intervention group
Group type: EXPERIMENTAL
Intervention: Bucindolol
Number of subjects: 226
Study 13680547 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 226
Study 10676668 — intervention group
Group type: EXPERIMENTAL
Intervention: Marine omega-3 fatty acids (4 g/day)
Number of subjects: 30
Study 10676668 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 9175408 — intervention group
Group type: EXPERIMENTAL
Intervention: School-based intervention
Number of subjects: 1364
Study 9175408 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 1364
Study 8380185 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (25 mg twice daily)
Number of subjects: 32
Study 8380185 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 3953429 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular verapamil (80 to 120 mg, 3 times a day)
Number of subjects: 22
Study 3953429 — intervention group
Group type: COMPARATOR
Intervention: Sustained-release verapamil (240 to 360 mg once a day)
Number of subjects: 22
Study 29661592 — intervention group
Group type: EXPERIMENTAL
Intervention: bipolar TURB (bTURB)
Number of subjects: 716
Study 27920513 — intervention group
Group type: EXPERIMENTAL
Intervention: Discair® inhalation (18 μg once-daily)
Number of subjects: 58
Study 27920513 — intervention group
Group type: COMPARATOR
Intervention: HandiHaler® inhalation (18 μg once-daily)
Number of subjects: 58
Study 25015763 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25 mg repaglinide, oral, twice daily (group A)
Number of subjects: 43
Study 25015763 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25 mg repaglinide, oral, three times daily (group B)
Number of subjects: 43
Study 22618094 — intervention group
Group type: EXPERIMENTAL
Intervention: Assist/control plus volume guarantee (VG) ventilation
Number of subjects: 45
Study 22618094 — intervention group
Group type: COMPARATOR
Intervention: Assist/control (A/C)
Number of subjects: 45
Study 21302687 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine spray 10%
Number of subjects: 48
Study 21302687 — intervention group
Group type: COMPARATOR
Intervention: Tetracaine 2% solution
Number of subjects: 48
Study 17269956 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 group‐discussion sessions with self‐directed learning
Number of subjects: 77
Study 17269956 — intervention group
Group type: COMPARATOR
Intervention: 12 formal lectures
Number of subjects: 77
Study 15481062 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral 6MP plus prednisone (OP)
Number of subjects: 1060
Study 15481062 — intervention group
Group type: COMPARATOR
Intervention: Intravenous 6MP plus prednisone (IP)
Number of subjects: 1060
Study 15481062 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral 6MP plus dexamethasone (OD)
Number of subjects: 1060
Study 15481062 — intervention group
Group type: COMPARATOR
Intervention: Intravenous 6MP plus dexamethasone (ID)
Number of subjects: 1060
Study 15481062 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral 6MP during consolidation
Number of subjects: 1060
Study 15481062 — intervention group
Group type: COMPARATOR
Intervention: Intravenous 6MP during consolidation
Number of subjects: 1060
Study 12043766 — intervention group
Group type: EXPERIMENTAL
Intervention: No tourniquet
Number of subjects: 34
Study 12043766 — intervention group
Group type: COMPARATOR
Intervention: Tourniquet
Number of subjects: 34
Study 12043766 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 34
Study 10210339 — intervention group
Group type: COMPARATOR
Intervention: 4 litres of PEG-saline solution and 15 mg of bisacodyl (SELG-4)
Number of subjects: 348
Study 10210339 — intervention group
Group type: COMPARATOR
Intervention: 156 mg of sennosides, 15 g of magnesium sulphate, and 2 litres of water (SennMg)
Number of subjects: 348
Study 10210339 — intervention group
Group type: COMPARATOR
Intervention: 156 mg of sennosides and 2 litres of PEG-saline solution (SennSELG)
Number of subjects: 348
Study 7887640 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.75 mg TAP-144-SR
Number of subjects: 106
Study 7887640 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5 mg TAP-144-SR
Number of subjects: 106
Study 2240542 — intervention group
Group type: EXPERIMENTAL
Intervention: Lignocaine‐prilocaine cream applied for 5 minutes
Number of subjects: 120
Study 2240542 — intervention group
Group type: EXPERIMENTAL
Intervention: Lignocaine‐prilocaine cream applied for 60 minutes
Number of subjects: 120
Study 2240542 — intervention group
Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 120
Study 2240542 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 120
Study 1120946 — intervention group
Group type: EXPERIMENTAL
Intervention: Success treatment for underachievers
Number of subjects: 22
Study 1120946 — intervention group
Group type: EXPERIMENTAL
Intervention: Failure treatment for overachievers
Number of subjects: 22
Study 31298712 — intervention group
Group type: EXPERIMENTAL
Intervention: Medicaid insurance type
Number of subjects: 194
Study 31298712 — intervention group
Group type: EXPERIMENTAL
Intervention: Private insurance type
Number of subjects: 194
Study 31298712 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinics with more than 3 practitioners
Number of subjects: 194
Study 31298712 — intervention group
Group type: COMPARATOR
Intervention: Clinics with single practitioners
Number of subjects: 194
Study 31298712 — intervention group
Group type: COMPARATOR
Intervention: Insurance status (Medicaid vs Private)
Number of subjects: 194
Study 31298712 — intervention group
Group type: COMPARATOR
Intervention: Clinics offering medications for opioid use disorders
Number of subjects: 194
Study 28668575 — intervention group
Group type: EXPERIMENTAL
Intervention: MenC‐TT vaccine
Number of subjects: 501
Study 28668575 — intervention group
Group type: EXPERIMENTAL
Intervention: MenACWY‐TT vaccine
Number of subjects: 501
Study 26714417 — intervention group
Group type: EXPERIMENTAL
Intervention: Paternal lymphocytes combined with vitamin D3
Number of subjects: 0
Study 26714417 — intervention group
Group type: COMPARATOR
Intervention: Paternal lymphocytes alone (Control)
Number of subjects: 0
Study 23759085 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar endometrial ablation
Number of subjects: 126
Study 23759085 — intervention group
Group type: COMPARATOR
Intervention: Balloon ablation
Number of subjects: 126
Study 21631695 — intervention group
Group type: EXPERIMENTAL
Intervention: Dutasteride 0.5 mg once daily
Number of subjects: 1630
Study 21631695 — intervention group
Group type: COMPARATOR
Intervention: Finasteride 5 mg once daily
Number of subjects: 1630
Study 18828959 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled human insulin (EXU)
Number of subjects: 1290
Study 17007384 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy with high expressions of CD44H
Number of subjects: 62
Study 17007384 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy with low expressions of CD44H
Number of subjects: 62
Study 17007384 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy with high expressions of nm23H1
Number of subjects: 62
Study 17007384 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy with low expressions of nm23H1
Number of subjects: 62
Study 17007384 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy
Number of subjects: 62
Study 14508195 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of irbesartan 150 mg and fosinopril 20 mg
Number of subjects: 12
Study 14508195 — intervention group
Group type: COMPARATOR
Intervention: Fosinopril 20 mg
Number of subjects: 12
Study 14508195 — intervention group
Group type: COMPARATOR
Intervention: Irbesartan 300 mg
Number of subjects: 12
Study 14508195 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 11101060 — intervention group
Group type: EXPERIMENTAL
Intervention: Delavirdine plus adefovir dipivoxil
Number of subjects: 7
Study 11101060 — intervention group
Group type: COMPARATOR
Intervention: Delavirdine
Number of subjects: 7
Study 8829189 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic antibiotics (ceftazidime, amikacine, and metronidazole for 10 days)
Number of subjects: 23
Study 8829189 — intervention group
Group type: COMPARATOR
Intervention: Nonantibiotic treatment
Number of subjects: 23
Study 1463170 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 ml bupivacaine 0.125%
Number of subjects: 30
Study 1463170 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 ml bupivacaine 0.125%
Number of subjects: 30
Study 1463170 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 ml bupivacaine 0.125%
Number of subjects: 30
Study 6422864 — intervention group
Group type: EXPERIMENTAL
Intervention: Total parenteral nutrition
Number of subjects: 59
Study 6422864 — intervention group
Group type: COMPARATOR
Intervention: Transpyloric feeding
Number of subjects: 59
Study 30700348 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin sodium combined with magnesium sulfate
Number of subjects: 103
Study 30700348 — intervention group
Group type: COMPARATOR
Intervention: Magnesium sulfate (control)
Number of subjects: 103
Study 29844423 — intervention group
Group type: EXPERIMENTAL
Intervention: Graduated Compression Stockings (GCS) alone (Group A)
Number of subjects: 625
Study 29844423 — intervention group
Group type: EXPERIMENTAL
Intervention: GCS + Low Molecular Weight Heparin (LMWH) (Group B)
Number of subjects: 625
Study 29844423 — intervention group
Group type: EXPERIMENTAL
Intervention: GCS + Intermittent Pneumatic Compression (IPC) (Group C)
Number of subjects: 625
Study 29844423 — intervention group
Group type: EXPERIMENTAL
Intervention: GCS + IPC + LMWH (Group D)
Number of subjects: 625
Study 29844423 — intervention group
Group type: EXPERIMENTAL
Intervention: LMWH-treated patients (Group B + Group D)
Number of subjects: 625
Study 29844423 — intervention group
Group type: COMPARATOR
Intervention: Non-LMWH-treated patients (Group A + Group C)
Number of subjects: 625
Study 27378312 — intervention group
Group type: EXPERIMENTAL
Intervention: Watermelon juice supplementation (300 mL·day−1 for 16 days)
Number of subjects: 8
Study 27378312 — intervention group
Group type: COMPARATOR
Intervention: Placebo (apple juice concentrate)
Number of subjects: 8
Study 27378312 — intervention group
Group type: COMPARATOR
Intervention: Control (no supplementation)
Number of subjects: 8
Study 27378312 — intervention group
Group type: EXPERIMENTAL
Intervention: Watermelon juice supplementation
Number of subjects: 8
Study 27378312 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 8
Study 25026923 — intervention group
Group type: EXPERIMENTAL
Intervention: Vegan diet
Number of subjects: 18
Study 25026923 — intervention group
Group type: COMPARATOR
Intervention: Low-calorie diet
Number of subjects: 18
Study 25026923 — intervention group
Group type: EXPERIMENTAL
Intervention: Facebook group engagement
Number of subjects: 18
Study 22192495 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodine-125 ((125)I) brachytherapy
Number of subjects: 259
Study 22192495 — intervention group
Group type: COMPARATOR
Intervention: Palladium-103 ((103)Pd) brachytherapy
Number of subjects: 259
Study 19294551 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceptance of stuttering
Number of subjects: 11
Study 19294551 — intervention group
Group type: EXPERIMENTAL
Intervention: Work-related speaking situations
Number of subjects: 11
Study 19294551 — intervention group
Group type: EXPERIMENTAL
Intervention: Retirement
Number of subjects: 11
Study 19294551 — intervention group
Group type: EXPERIMENTAL
Intervention: Learned and self-devised techniques
Number of subjects: 11
Study 19294551 — intervention group
Group type: EXPERIMENTAL
Intervention: Desire for effective treatment
Number of subjects: 11
Study 16546854 — intervention group
Group type: EXPERIMENTAL
Intervention: Toothpaste containing sodium fluoride (1500 ppm)
Number of subjects: 39
Study 16546854 — intervention group
Group type: EXPERIMENTAL
Intervention: Toothpaste containing amine fluoride (1250 ppm)
Number of subjects: 39
Study 16546854 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 39
Study 12662366 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy prescription diet (n=16)
Number of subjects: 53
Study 12662366 — intervention group
Group type: COMPARATOR
Intervention: Healthy eating diet (n=11)
Number of subjects: 53
Study 11138765 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotypic information about teammates (gender stereotypes in Experiment 1, occupational stereotypes in Experiments 2 to 4)
Number of subjects: 0
Study 11138765 — intervention group
Group type: EXPERIMENTAL
Intervention: Collective condition (Experiment 3)
Number of subjects: 0
Study 11138765 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticipation of working on a collective task (Experiment 4)
Number of subjects: 0
Study 9103704 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecystectomy without peritoneal closure (n = 63)
Number of subjects: 129
Study 9103704 — intervention group
Group type: COMPARATOR
Intervention: Cholecystectomy with peritoneal closure (n = 66)
Number of subjects: 129
Study 1397878 — intervention group
Group type: EXPERIMENTAL
Intervention: Loxiglumide (10 mg.kg‐1.h‐1)
Number of subjects: 12
Study 4028627 — intervention group
Group type: EXPERIMENTAL
Intervention: Acifran 100 mg t.i.d.
Number of subjects: 30
Study 4028627 — intervention group
Group type: EXPERIMENTAL
Intervention: Acifran 300 mg t.i.d.
Number of subjects: 30
Study 4028627 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 31601603 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic dispensing from private pharmacies
Number of subjects: 1537
Study 31601603 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefixime and third-generation cephalosporins
Number of subjects: 1537
Study 31601603 — intervention group
Group type: COMPARATOR
Intervention: Unlicensed pharmacies
Number of subjects: 1537
Study 31601603 — intervention group
Group type: COMPARATOR
Intervention: Young patients
Number of subjects: 1537
Study 29340623 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab (RTX) - four weekly infusions of 375 mg/m2
Number of subjects: 89
Study 26829923 — intervention group
Group type: EXPERIMENTAL
Intervention: Maekmoondong-tang
Number of subjects: 0
Study 26829923 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 25537538 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung recruitment maneuver (LRM) with positive end-expiratory pressure (PEEP)
Number of subjects: 30
Study 22342390 — intervention group
Group type: EXPERIMENTAL
Intervention: Coenzyme Q10 150 mg/d
Number of subjects: 51
Study 22342390 — intervention group
Group type: EXPERIMENTAL
Intervention: Coenzyme Q10 60 mg/d
Number of subjects: 51
Study 20145599 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous transluminal renal artery stent placement (PTRS)
Number of subjects: 0
Study 20145599 — intervention group
Group type: EXPERIMENTAL
Intervention: Embolic protection devices
Number of subjects: 0
Study 20145599 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast induced nephropathy prevention practices
Number of subjects: 0
Study 16705003 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic steroids (Methyl prednisolone 0.5 mg/kg/day i.v. in two divided doses)
Number of subjects: 51
Study 16705003 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized steroids (Budecort 50 micrograms nebulized every 12 hours)
Number of subjects: 51
Study 16705003 — intervention group
Group type: COMPARATOR
Intervention: Control group (no steroids)
Number of subjects: 51
Study 16503676 — intervention group
Group type: EXPERIMENTAL
Intervention: Jump Squat (JS) group performed 1 set of 40‐kg LCMJs
Number of subjects: 9
Study 16503676 — intervention group
Group type: COMPARATOR
Intervention: Control (CON) group performed 1 set of 20‐kg LCMJs
Number of subjects: 9
Study 12900237 — intervention group
Group type: EXPERIMENTAL
Intervention: HumanOptics accommodating 1CU(R) IOL
Number of subjects: 42
Study 12900237 — intervention group
Group type: COMPARATOR
Intervention: Eurocrystal IFP 3G 6.00 (control group)
Number of subjects: 42
Study 10882616 — intervention group
Group type: EXPERIMENTAL
Intervention: zidovudine plus stavudine (d4T)
Number of subjects: 0
Study 10882616 — intervention group
Group type: EXPERIMENTAL
Intervention: didanosine (ddI)
Number of subjects: 0
Study 10882616 — intervention group
Group type: EXPERIMENTAL
Intervention: didanosine (ddI) plus zidovudine
Number of subjects: 0
Study 10882616 — intervention group
Group type: COMPARATOR
Intervention: zidovudine plus d4T
Number of subjects: 0
Study 8761371 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum prostate-specific antigen (PSA) screening
Number of subjects: 600
Study 8761371 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of free to total PSA ratio with a cut-off level of 0.20
Number of subjects: 600
Study 1555499 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemodilution (group I): six venesections of 400 ml each followed by the injection of 500 ml low-molecular dextran (10%)
Number of subjects: 20
Study 1555499 — intervention group
Group type: COMPARATOR
Intervention: Pentoxifylline (group II): 400 mg four times daily by mouth after initial intravenous loading
Number of subjects: 20
Study 3924216 — intervention group
Group type: EXPERIMENTAL
Intervention: Biosynthetic human insulin (1 mU/kg/min)
Number of subjects: 24
Study 3924216 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin antibodies presence
Number of subjects: 24
Study 3924216 — intervention group
Group type: COMPARATOR
Intervention: Insulin action loss rate
Number of subjects: 24
Study 3924216 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate concentrations of insulin antibodies
Number of subjects: 24
Study 30134866 — intervention group
Group type: EXPERIMENTAL
Intervention: ASET
Number of subjects: 144
Study 30134866 — intervention group
Group type: EXPERIMENTAL
Intervention: EW
Number of subjects: 144
Study 30134866 — intervention group
Group type: COMPARATOR
Intervention: JNL
Number of subjects: 144
Study 26526713 — intervention group
Group type: EXPERIMENTAL
Intervention: Etrolizumab (exact dosage and duration not specified)
Number of subjects: 331
Study 26526713 — intervention group
Group type: COMPARATOR
Intervention: Rectosigmoidoscopy
Number of subjects: 331
Study 26526713 — intervention group
Group type: COMPARATOR
Intervention: Colonoscopy
Number of subjects: 331
Study 26526713 — intervention group
Group type: COMPARATOR
Intervention: Endoscopic healing defined as MCSe of 0
Number of subjects: 331
Study 25051000 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibration-enhanced static stretching
Number of subjects: 21
Study 25051000 — intervention group
Group type: COMPARATOR
Intervention: Static stretching without vibration
Number of subjects: 21
Study 22879417 — intervention group
Group type: EXPERIMENTAL
Intervention: PRK (n = 20)
Number of subjects: 45
Study 22879417 — intervention group
Group type: EXPERIMENTAL
Intervention: LASIK (n = 25)
Number of subjects: 45
Study 20730362 — intervention group
Group type: EXPERIMENTAL
Intervention: HVPC(-) group (conventional treatment plus negative polarity HVPC)
Number of subjects: 28
Study 20730362 — intervention group
Group type: EXPERIMENTAL
Intervention: HVPC+ group (conventional treatment plus positive polarity HVPC)
Number of subjects: 28
Study 20730362 — intervention group
Group type: COMPARATOR
Intervention: CG (control group with conventional treatment)
Number of subjects: 28
Study 18664156 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical tacrolimus 0.1% ointment
Number of subjects: 32
Study 18664156 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 32
Study 15976242 — intervention group
Group type: COMPARATOR
Intervention: Capdevila approach (group C; n = 30)
Number of subjects: 60
Study 15976242 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Winnie approach (group W; n = 30)
Number of subjects: 60
Study 12721399 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenium (Se)
Number of subjects: 109